JP2019526571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526571A5 JP2019526571A5 JP2019511720A JP2019511720A JP2019526571A5 JP 2019526571 A5 JP2019526571 A5 JP 2019526571A5 JP 2019511720 A JP2019511720 A JP 2019511720A JP 2019511720 A JP2019511720 A JP 2019511720A JP 2019526571 A5 JP2019526571 A5 JP 2019526571A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- composition according
- acid
- neurotransmission
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1614834.8 | 2016-09-01 | ||
| GBGB1614834.8A GB201614834D0 (en) | 2016-09-01 | 2016-09-01 | Treatment of dementia |
| PCT/EP2017/071437 WO2018041739A1 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526571A JP2019526571A (ja) | 2019-09-19 |
| JP2019526571A5 true JP2019526571A5 (https=) | 2020-10-01 |
| JP7066679B2 JP7066679B2 (ja) | 2022-05-13 |
Family
ID=57139937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511720A Active JP7066679B2 (ja) | 2016-09-01 | 2017-08-25 | 認知症の処置 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10842796B2 (https=) |
| EP (1) | EP3506904B1 (https=) |
| JP (1) | JP7066679B2 (https=) |
| KR (1) | KR102559354B1 (https=) |
| CN (1) | CN109890391B (https=) |
| AU (1) | AU2017318333B2 (https=) |
| DK (1) | DK3506904T3 (https=) |
| ES (1) | ES2847929T3 (https=) |
| GB (1) | GB201614834D0 (https=) |
| HR (1) | HRP20210162T1 (https=) |
| MX (1) | MX384442B (https=) |
| MY (1) | MY187564A (https=) |
| PL (1) | PL3506904T3 (https=) |
| PT (1) | PT3506904T (https=) |
| SG (1) | SG11201901125TA (https=) |
| SI (1) | SI3506904T1 (https=) |
| WO (1) | WO2018041739A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2013191B3 (en) | 2006-03-29 | 2019-02-27 | Wista Laboratories Ltd. | 3,7-diamino-10h-phenothiazine salts and their use |
| DK3121169T3 (da) | 2006-07-11 | 2022-02-28 | Wista Lab Ltd | Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser |
| KR102592614B1 (ko) | 2016-07-25 | 2023-10-24 | 위스타 레보레이토리스 리미티드 | 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage) |
| DK3826639T3 (da) * | 2018-07-26 | 2024-09-23 | Wista Lab Ltd | Optimeret dosering af diaminophenothiaziner i populationer |
| WO2020048593A1 (en) | 2018-09-05 | 2020-03-12 | Wista Laboratories Ltd. | Network methods for neurodegenerative diseases |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| JP2023524146A (ja) * | 2020-05-05 | 2023-06-08 | ウィスタ ラボラトリーズ リミテッド | 低酸素血症の治療に使用されるメチルチオニニウム化合物 |
| GB202006659D0 (en) * | 2020-05-05 | 2020-06-17 | Wista Lab Ltd | Therapeutic treatments |
| WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| EP4342451A1 (en) * | 2022-09-22 | 2024-03-27 | Galenicum Health SLU | Pharmaceutical compositions and manufacturing methods thereof |
| US20240115579A1 (en) * | 2022-09-22 | 2024-04-11 | Galenicum Health S.L.U. | Pharmaceutical compositions and manufacturing methods thereof |
| WO2024178120A2 (en) * | 2023-02-21 | 2024-08-29 | Prosetta Biosciences, Inc. | Phenothiazinyl compounds and uses |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| WO2003101458A1 (en) | 2002-05-31 | 2003-12-11 | H. Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| AU2005286235C1 (en) | 2004-09-23 | 2013-08-22 | TauRx Therapeutics Management Ltd | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including Methylthioninium Chloride (MTC) |
| EP2013191B3 (en) * | 2006-03-29 | 2019-02-27 | Wista Laboratories Ltd. | 3,7-diamino-10h-phenothiazine salts and their use |
| MY162640A (en) * | 2006-03-29 | 2017-06-30 | Wista Lab Ltd | Thioninium compounds and their use |
| FR2899107B1 (fr) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
| DK3121169T3 (da) | 2006-07-11 | 2022-02-28 | Wista Lab Ltd | Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser |
| FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
| US9034890B2 (en) * | 2006-11-15 | 2015-05-19 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| CN101820884B (zh) | 2007-06-19 | 2013-08-28 | 维斯塔实验室有限公司 | 用于治疗轻度认知缺损的吩噻嗪化合物 |
| CA3027974C (en) | 2007-10-03 | 2022-03-15 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
| DK3378856T3 (da) | 2009-09-24 | 2020-12-21 | Wista Lab Ltd | Krystallinske methylthioniniumchlorid-hydrater |
| PL2480540T3 (pl) | 2009-09-24 | 2018-05-30 | Wista Laboratories Ltd. | Pentahydrat chlorku metylotioninowego, jego wytwarzanie i zastosowanie farmaceutyczne |
| EA025033B1 (ru) | 2011-02-11 | 2016-11-30 | Уиста Лэборэтэриз Лтд. | Диаминиевые соли фенотиазина и их применение |
| CN102936244B (zh) * | 2012-12-04 | 2015-02-04 | 合肥工业大学 | 一种他克林-吩噻嗪异二联体类化合物及其制备方法 |
-
2016
- 2016-09-01 GB GBGB1614834.8A patent/GB201614834D0/en not_active Ceased
-
2017
- 2017-08-25 PL PL17761842T patent/PL3506904T3/pl unknown
- 2017-08-25 ES ES17761842T patent/ES2847929T3/es active Active
- 2017-08-25 SG SG11201901125TA patent/SG11201901125TA/en unknown
- 2017-08-25 JP JP2019511720A patent/JP7066679B2/ja active Active
- 2017-08-25 DK DK17761842.8T patent/DK3506904T3/da active
- 2017-08-25 US US16/329,611 patent/US10842796B2/en active Active
- 2017-08-25 MY MYPI2019001119A patent/MY187564A/en unknown
- 2017-08-25 WO PCT/EP2017/071437 patent/WO2018041739A1/en not_active Ceased
- 2017-08-25 AU AU2017318333A patent/AU2017318333B2/en active Active
- 2017-08-25 CN CN201780067154.4A patent/CN109890391B/zh active Active
- 2017-08-25 EP EP17761842.8A patent/EP3506904B1/en active Active
- 2017-08-25 MX MX2019002429A patent/MX384442B/es unknown
- 2017-08-25 SI SI201730630T patent/SI3506904T1/sl unknown
- 2017-08-25 KR KR1020197009175A patent/KR102559354B1/ko active Active
- 2017-08-25 HR HRP20210162TT patent/HRP20210162T1/hr unknown
- 2017-08-25 PT PT177618428T patent/PT3506904T/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526571A5 (https=) | ||
| JP6795517B2 (ja) | ５−芳香族アルキニル基置換ベンズアミド系化合物並びにその製造方法、薬物組成物及び使用 | |
| JP7514534B2 (ja) | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 | |
| AU2014368961B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| TWI791507B (zh) | 使用ccr3-抑制劑治療老化相關損傷之方法及組合物 | |
| HRP20210162T1 (hr) | Liječenje demencije | |
| JP2015532295A5 (https=) | ||
| EP3555100A1 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| JP2021503480A (ja) | トラジピタントを用いた胃腸疾患の治療方法 | |
| JP6023926B2 (ja) | 認知症治療のための５−ｈｔ４受容体アゴニスト | |
| JP2019521964A5 (https=) | ||
| BRPI0808353B1 (pt) | Usos de amidas do ácido 3-aril-3-hidróxi-2-amino-propiônico, amidas do ácido 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados | |
| US8598180B2 (en) | Tetrahydroindolone derivatives for treatment of neurological conditions | |
| JP2019518736A5 (https=) | ||
| CN107709326A (zh) | 降低应激诱导的p‑tau的三唑并吡啶和三唑并嘧啶 | |
| JP7090344B2 (ja) | セロトニン３受容体アゴニストによる疼痛の治療 | |
| CN102365269A (zh) | 用于治疗认知缺损的新药物 | |
| BR112021004938A2 (pt) | métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3 | |
| JP4598674B2 (ja) | 統合失調症治療剤 | |
| CN114761008B (zh) | 用于在患有痴呆的患者中治疗行为和心理症状的方法 | |
| US20090156609A1 (en) | Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperzaine compounds | |
| WO2026024223A1 (en) | Small molecule inhibitors and methods thereof | |
| JP2010530900A (ja) | 中枢神経系活性を有する置換ピロリジン化合物 | |
| HK40092010A (zh) | GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法 | |
| WO2010029958A1 (ja) | 侵害受容性疼痛の新規治療用医薬組成物 |